Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2020-12-28 17:06 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
$518,234 | |
Filed 2020-12-28 17:05 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
Filed 2020-12-28 16:22 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
Filed 2020-12-28 16:22 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
$518,234 | |
Filed 2020-12-28 16:20 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
116,667 | |
Filed 2020-11-05 11:15 Tx date 2020-11-01 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$249,000
+20,000 vol $12.45 each |
76,667 | |
Filed 2020-11-05 11:13 Tx date 2020-11-01 |
$TRIL
Trillium Therapeutics Inc. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$622,500
+50,000 vol $12.45 each |
56,667 | |
Filed 2020-01-02 16:50 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$16,205 vol $1.16 each |
$514,286 | |
Filed 2019-11-11 14:55 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$498,081 | |
Filed 2019-10-02 15:31 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$42,895 vol $0.4467 each |
$149,748 | |
Filed 2019-07-03 14:04 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$42,531 vol $0.4358 each |
$106,853 | |
Filed 2019-04-05 10:09 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$19,815 vol $0.92 each |
$64,322 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$44,507 | |
Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,390 vol $12.18 each |
$15,326 | |
Filed 2016-11-15 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$90,003
+7,936 vol $11.34 each |
||
Filed 2016-11-15 Tx date 2014-03-10 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-11-15 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$7,936 vol $11.34 each |
$7,936 | |
Filed 2016-11-15 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$90,003
+7,936 vol $11.34 each |
||
Filed 2016-11-14 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$90,003
+7,936 vol $11.34 each |
16,567 | |
Filed 2015-11-20 Tx date 2015-11-19 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$39,993
+2,069 vol $19.33 each |
8,631 | |
Filed 2015-08-25 Tx date 2015-06-16 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$10,003
+340 vol $29.42 each |
||
Filed 2015-08-25 Tx date 2014-03-10 |
$TR
Stem Cell Therapeutics Corp. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-08-25 Tx date 2014-03-10 |
$TR
Stem Cell Therapeutics Corp. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-08-25 Tx date 2014-05-27 |
$TR
Stem Cell Therapeutics Corp. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$40,000
+143,885 vol $0.278 each |
||
Filed 2015-08-25 Tx date 2014-05-27 |
$TR
Stem Cell Therapeutics Corp. |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$40,000
+143,885 vol $0.278 each |
||
Filed 2015-08-25 Tx date 2014-03-10 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-08-25 Tx date 2014-05-27 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$40,000
+143,885 vol $0.278 each |
143,885 | |
Filed 2015-08-25 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
37 - Stock split or consolidation
|
$-40,000.03
-143,885 vol $0.278 each |
0 | |
Filed 2015-08-25 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
37 - Stock split or consolidation
|
$39,998
+4,796 vol $8.34 each |
4,796 | |
Filed 2015-08-25 Tx date 2015-05-27 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$39,992
+1,426 vol $28.05 each |
6,222 | |
Filed 2015-08-25 Tx date 2015-06-16 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$10,003
+340 vol $29.42 each |
6,562 | |
Filed 2015-08-25 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
37 - Stock split or consolidation
|
$-40,000.03
-143,885 vol $0.278 each |
||
Filed 2015-08-25 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
37 - Stock split or consolidation
|
$-40,000.03
-143,885 vol $0.278 each |
||
Filed 2015-08-25 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
37 - Stock split or consolidation
|
$39,998
+4,796 vol $8.34 each |
||
Filed 2015-08-25 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
37 - Stock split or consolidation
|
$39,998
+4,796 vol $8.34 each |
||
Filed 2015-08-25 Tx date 2015-05-27 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$39,992
+1,426 vol $28.05 each |
||
Filed 2015-08-25 Tx date 2015-05-27 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$39,992
+1,426 vol $28.05 each |
||
Filed 2015-08-25 Tx date 2015-06-16 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$10,003
+340 vol $29.42 each |
||
Filed 2015-06-17 Tx date 2015-06-16 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$10,003
+340 vol $29.42 each |
6,562 | |
Filed 2015-06-12 Tx date 2015-05-27 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
97 - Other
|
$39,992
+1,426 vol $28.05 each |
6,222 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
37 - Stock split or consolidation
|
$39,998
+4,796 vol $8.34 each |
4,796 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Units Deferred Share Units
37 - Stock split or consolidation
|
$-40,000.03
-143,885 vol $0.278 each |
0 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+6,667 vol |
6,667 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Reynolds, Thomas
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-200,000 vol |
0 |